1. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide‐containing regimens. (18th November 2016) Authors: Sanchez, Larysa; Vesole, David H.; Richter, Joshua R.; Biran, Noa; Bilotti, Elizabeth; McBride, Laura; Anand, Palka; Ivanovski, Kristin; Siegel, David S. Journal: British journal of haematology Issue: Volume 176:Number 3(2017) Page Start: 440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma. Issue 11 (17th September 2021) Authors: Biran, Noa; Gourna Paleoudis, Elli; Feinman, Rena; Vesole, David H.; Zenreich, Joshua; Wang, Shuqi; Ahn, Jaeil; Bansal, Meena; Rowley, Scott; Donato, Michele; Pecora, Andrew L.; Richter, Joshua; Anand, Palka; McBride, Laura; Ivanovski, Kristin; Korngold, Robert; Siegel, David S. Journal: American journal of hematology Issue: Volume 96:Issue 11(2021) Page Start: E430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. (27th May 2015) Authors: Vesole, David H.; Bilotti, Elizabeth; Richter, Joshua R.; McNeill, Ann; McBride, Laura; Raucci, Laura; Anand, Palka; Bednarz, Urszula; Ivanovski, Kristin; Smith, Judith; Batra, Veena; Aleman, Adolfo; Sims, Taliah; Guerrero, Laura; Mato, Anthony; Siegel, David S. Journal: British journal of haematology Issue: Volume 171:Number 1(2015:Oct.) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗